Aclaris Therapeutics Inc [NASDAQ: ACRS] plunged by -$0.13 during the normal trading session on Tuesday and reaching a high of $1.71 during the day while it closed the day at $1.55.
Aclaris Therapeutics Inc stock has also loss -4.32% of its value over the past 7 days. However, ACRS stock has inclined by 13.97% in the 3 months of the year. Over the past six months meanwhile, it has lost -36.73% and gained 14.81% year-on date.
The market cap for ACRS stock reached $167.83 million, with 108.27 million shares outstanding and 92.25 million shares in the current float. Compared to the average trading volume of 890.73K shares, ACRS reached a trading volume of 6024851 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Aclaris Therapeutics Inc [ACRS]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ACRS shares is $7.86 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ACRS stock is a recommendation set at 1.29. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Piper Sandler have made an estimate for Aclaris Therapeutics Inc shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on July 10, 2025. While these analysts kept the previous recommendation, Wedbush raised their target price to Outperform. The new note on the price target was released on May 28, 2025, representing the official price target for Aclaris Therapeutics Inc stock.
The Price to Book ratio for the last quarter was 1.16, with the Price to Cash per share for the same quarter was set at 0.97.
ACRS stock trade performance evaluation
Aclaris Therapeutics Inc [ACRS] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -4.32. With this latest performance, ACRS shares gained by 5.44% in over the last four-week period, additionally sinking by -36.73% over the last 6 months – not to mention a drop of -37.50% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ACRS stock in for the last two-week period is set at 48.77, with the RSI for the last a single of trading hit 0.1023, and the three-weeks RSI is set at 0.1003 for Aclaris Therapeutics Inc [ACRS]. The present Moving Average for the last 50 days of trading for this stock 1.4918, while it was recorded at 1.6580 for the last single week of trading, and 1.9771 for the last 200 days.
Aclaris Therapeutics Inc [ACRS]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Aclaris Therapeutics Inc [ACRS] shares currently have an operating margin of -302.92% and a Gross Margin at 14.87%. Aclaris Therapeutics Inc’s Net Margin is presently recorded at -732.42%.
Aclaris Therapeutics Inc (ACRS) Capital Structure & Debt Analysis
According to recent financial data for Aclaris Therapeutics Inc. ( ACRS), the Return on Equity (ROE) stands at -91.03%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -69.97%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Aclaris Therapeutics Inc’s Return on Invested Capital (ROIC) is -89.15%, showcasing its effectiveness in deploying capital for earnings.
Aclaris Therapeutics Inc (ACRS) Efficiency & Liquidity Metrics
Based on Aclaris Therapeutics Inc’s (ACRS) latest financial statements, the Debt-to-Equity Ratio is 0.02%, indicating its reliance on debt financing relative to shareholder equity.
Aclaris Therapeutics Inc (ACRS) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Aclaris Therapeutics Inc. (ACRS) effectively leverages its workforce, generating an average of -$2034531.25 per employee. The company’s liquidity position is robust, with a Current Ratio of 5.06% and a Quick Ratio of 5.06%, indicating strong ability to cover short-term liabilities.
Earnings per share (EPS) analysis for Aclaris Therapeutics Inc [ACRS] stock
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ACRS. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Aclaris Therapeutics Inc go to 27.58%.
Aclaris Therapeutics Inc [ACRS]: Institutional Ownership
There are presently around $87.83%, or 90.26% of ACRS stock, in the hands of institutional investors. The top three institutional holders of ACRS stocks are: BML CAPITAL MANAGEMENT, LLC with ownership of 12.99 million shares, which is approximately 18.2184%. VANGUARD GROUP INC, holding 4.69 million shares of the stock with an approximate value of $$5.16 million in ACRS stocks shares; and VANGUARD GROUP INC, currently with $$3.67 million in ACRS stock with ownership which is approximately 4.6806%.
